Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Terapeutisk lægemiddelovervågning af Sunitinib og Pazopanib ved avanceret eller metastatisk nyrecellekarcinom (SUP-R)

17. november 2026 opdateret af: Institut Claudius Regaud

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study.

Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib).

The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

Studieoversigt

Status

Afsluttet

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

47

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Bordeaux, Frankrig, 33076
        • Institut Bergonie
      • Bordeaux, Frankrig, 33035
        • CHU DE BORDEAUX - Hôpital Saint-André
      • Limoges, Frankrig, 87042
        • CHU DE LIMOGES - Hôpital Dupuytren
      • Lyon, Frankrig, 69373
        • Centre Leon Berard
      • Marseille, Frankrig, 13273
        • Institut Paoli Calmettes
      • Montpellier, Frankrig, 34298
        • Institut Regional Du Cancer Montpellier
      • Rodez, Frankrig, 12027
        • CH RODEZ
      • Toulouse, Frankrig, 31059
        • Institut Claudius Regaud

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma.
  2. Measurable tumours as defined by RECIST criteria version 1.1.
  3. Age ≥ 18 years old.
  4. WHO Performance Status ≤ 2.
  5. Life expectancy ≥ 6 months.
  6. Adequate cardiac function (baseline Left Ventricular Ejection Fraction (LVEF) ≥ 50% determined by Multiple Gated Acquisition scan (MUGA) or echocardiography) and pulmonary function.
  7. Renal function defined as creatinine clearance (Cockcroft and Gault formula) > 30 mL/min.
  8. Adequate liver function defined as: total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN); Alanine AminoTansferase (ALAT) and Aspartate AminoTransferase (ASAT) ≤ 2.5 x ULN; Concomitant elevation in bilirubin and ASAT/ALAT above 1.0 x ULN is not allowed.
  9. Patients must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up.
  10. Negative pregnancy test for women in childbearing potential.
  11. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study (before study entry and until 30 days after the last administration of study treatment).
  12. Patients affiliated to a social health insurance.

Exclusion Criteria:

  1. Patients without any venous access for blood sampling.

  2. Hypersensitivity to the active substance or to any of the excipients.

  3. History or clinical evidence of central nervous system (CNS) metastases, except for individuals who have previously-treated CNS metastases.

  4. Corrected QT interval (QTc) > 480msecs using Bazett's formula.

  5. Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to:

    • Uncontrolled infection.
    • Cardiovascular conditions within the last 6 months such as cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New-York Heart Association (NYHA), clinically significant irregular heartbeat requiring medication.
    • Poorly controlled hypertension [defined as systolic blood pressure of ≥140 mmHg or diastolic pressure of ≥90 mmHg).
    • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months.

    Note: patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.

  6. Evidence of active bleeding or bleeding diathesis.

  7. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cytochrome P450 isoenzyme 3A4 (CYP3A4) within the last 14 days prior to inclusion and/or during the study.

  8. Patients already treated with an anticancer treatment in the previous four weeks or patient requiring anticancer treatment during the study (chemotherapy, immunotherapy, hormonotherapy, radiotherapy or surgery).

  9. Pregnant or breast-feeding women.

  10. Positive diagnostic of HIV, B and C hepatitis.

  11. Patients with serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with patient's safety, provision of informed consent, or compliance to study procedures.

  12. Patients who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Pazopanib

The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).

During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.

Aktiv komparator: Sunitinib

Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).

During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del I: Farmakokinetik - Pazopanib eller Sunitinib plasmakoncentrationer
Tidsramme: På dag 1 og dag 15 under cyklus 1 og cyklus 2 (cykluslængde er 6 uger)
På dag 1 og dag 15 under cyklus 1 og cyklus 2 (cykluslængde er 6 uger)
Del II: Effektivitet - Andel af patienter uden progression ved 1 år. Dette svarer til antallet af patienter uden progression efter 1 år blandt det samlede antal patienter i hver gruppe
Tidsramme: 5,5 år
5,5 år
Del I: Uønskede hændelser i henhold til NCI-toksicitetsskalaen (version 4.03)
Tidsramme: 1,5 år
1,5 år
Part II: Tolerance - Proportion of patients without treatment discontinuation due to adverse event (AE) during the first year.
Tidsramme: 5.5 years

This corresponds to the number of patients without treatment discontinuation due to AE among the total number of patients in each group.

5.5 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del I og II: Sikkerhed i henhold til klassificeringen af ​​NCI: Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03.
Tidsramme: 5,5 år
5,5 år
Part I and II: Objective Response (e.g. Complete or Partial Response)
Tidsramme: 5.5 years

Objective Response will be defined using RECIST Criteria version 1.1.

5.5 years
Part I and II:- Progression free survival.
Tidsramme: 5.5 years

Progression free survival is defined as the time from inclusion until progression (RECIST Criteria version 1.1) or death. Patients alive at last follow-up news are censored at this date.

5.5 years
Part I and II: Hand-foot syndrome (HFS)
Tidsramme: 5.5 years

Hand-foot syndrome (HFS) will be evaluated using the HFS-14 questionnaire. This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment.

5.5 years
Part I and II: Quality of life using the quality of life questionnaire (QLQ)-C30
Tidsramme: 5.5 years

Quality of life will be evaluated using the QLQ-C30 questionnaire

5.5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Christine CHEVREAU, MD, IUCT-O

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. november 2015

Primær færdiggørelse (Faktiske)

16. januar 2020

Studieafslutning (Faktiske)

16. januar 2020

Datoer for studieregistrering

Først indsendt

4. september 2015

Først indsendt, der opfyldte QC-kriterier

21. september 2015

Først opslået (Anslået)

22. september 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. november 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner